AB-3D3

AB-3D3 is a **humanized IgG1 monoclonal antibody** directed against **KAAG1**, a cell-surface protein reported by Alethia Biotherapeutics as being expressed in ovarian cancer. Publicly available company materials describe AB-3D3 as a **preclinical therapeutic program** for **ovarian cancer**, with activity in animal models showing reduction of micrometastatic tumors. No International Nonproprietary Name, marketed brand name, or clinical-stage registration was identified from the public sources reviewed, so the asset appears to remain an early-stage, sponsor-code antibody program rather than an approved or clinically established drug.

Other names

anti-KAAG1 antibodyanti-KAAG-1 antibodyanti-KAAG 1 antibodyanti-human KAAG1